Thiazolidinediones-PPAR-γ Agonists; for the treatment of Type II Diabetes Mellitus
Article Sidebar
Main Article Content
Abstract
Current treatment for diabetes mellitus cannot treat Insulin insensitivity, resistance, and destruction of the beta cells of the pancreas. Thiazolidinediones are the class of the drugs that binds to the PPAR-γ receptors and make proper utilization of secreted insulin by reducing insensitivity. It also reduces the lipid crowd in the liver. Increases the storage capacity in the adipose tissues for the triglycerides and the free fatty acid. The TZDs are reported with some side effects like CHF due to water retention, bone fracture, gain of the body weight, and bladder cancers are discussed in the review.
Downloads
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
References
B. B. Zhang and D. E. Moller, “New approaches in the treatment of type 2 diabetes,” CurrOpin Chem Biol, vol. 4, no. 4, pp. 461–467, Aug. 2000, doi: 10.1016/S1367-5931(00)00103-4.
R. A. DeFronzo, “Pharmacologic Therapy for Type 2 Diabetes Mellitus,” Ann Intern Med, vol. 131, no. 4, p. 281, Aug. 1999, doi: 10.7326/0003-4819-131-4-199908170-00008.
B. M. Spiegelman, “PPAR-gamma: adipogenic regulator and thiazolidinedione receptor.,” Diabetes, vol. 47, no. 4, pp. 507–514, Apr. 1998, doi: 10.2337/diabetes.47.4.507.
S. Rekha and S. Chandrashekhara, “Insilico proportional molecular docking study and analysis of insulinotropic activity of TZD derivatives by PPARγ activation,” Journal of Pharmaceutical Sciences and Research, vol. 9, pp. 1799–1808, May 2017.
L. Hevener, D. Reichart, and J. Olefsky, “Exercise and thiazolidinedione therapy normalize insulin action in the obese Zucker fatty rat.,” Diabetes, vol. 49, no. 12, pp. 2154–2159, Dec. 2000, doi: 10.2337/diabetes.49.12.2154.
Cariou, B. Charbonnel, and B. Staels, “Thiazolidinediones and PPARγ agonists: time for a reassessment,” Trends in Endocrinology & Metabolism, vol. 23, no. 5, pp. 205–215, May 2012, doi: 10.1016/j.tem.2012.03.001.
S. E. Inzucchi, “Oral Antihyperglycemic Therapy for Type 2 Diabetes,” JAMA, vol. 287, no. 3, p. 360, Jan. 2002, doi: 10.1001/jama.287.3.360.
Nourparvar, A. Bulotta, U. Di Mario, and R. Perfetti, “Novel strategies for the pharmacological management of type 2 diabetes,” Trends Pharmacol Sci, vol. 25, no. 2, pp. 86–91, Feb. 2004, doi: 10.1016/j.tips.2003.12.007.
N. Thangavel, M. Al Bratty, S. Akhtar Javed, W. Ahsan, and H. A. Alhazmi, “Targeting Peroxisome Proliferator-Activated Receptors Using Thiazolidinediones: Strategy for Design of Novel Antidiabetic Drugs,” Int J Med Chem, vol. 2017, pp. 1–20, Jun. 2017, doi: 10.1155/2017/1069718.
R. R. Henry, “THIAZOLIDINEDIONES,” Endocrinol Metab Clin North Am, vol. 26, no. 3, pp. 553–573, Sep. 1997, doi: 10.1016/S0889-8529(05)70267-X.
H. Yki-Järvinen, “Thiazolidinediones,” New England Journal of Medicine, vol. 351, no. 11, pp. 1106–1118, Sep. 2004, doi: 10.1056/NEJMra041001.
K. Schoonjans and J. Auwerx, “Thiazolidinediones: an update,” The Lancet, vol. 355, no. 9208, pp. 1008–1010, Mar. 2000, doi: 10.1016/S0140-6736(00)90002-3.
S. V. Arnold et al., “Understanding Contemporary Use of Thiazolidinediones,” Circ Heart Fail, vol. 12, no. 6, Jun. 2019, doi: 10.1161/CIRCHEARTFAILURE.118.005855.
S. E. Kahn et al., “Glycemic Durability of Rosiglitazone, Metformin, or Glyburide Monotherapy,” New England Journal of Medicine, vol. 355, no. 23, pp. 2427–2443, Dec. 2006, doi: 10.1056/NEJMoa066224.
M. J. Nanjan, M. Mohammed, B. R. Prashantha Kumar, and M. J. N. Chandrasekar, “Thiazolidinediones as antidiabetic agents: A critical review,” Bioorg Chem, vol. 77, pp. 548–567, Apr. 2018, doi: 10.1016/j.bioorg.2018.02.009.
J. S. Eggleton and I. Jialal, Thiazolidinediones. 2023.
B. Cariou, B. Charbonnel, and B. Staels, “Thiazolidinediones and PPARγ agonists: time for a reassessment,” Trends in Endocrinology & Metabolism, vol. 23, no. 5, pp. 205–215, May 2012, doi: 10.1016/j.tem.2012.03.001.
C. J. Bailey, “Thiazolidinediones,” in xPharm: The Comprehensive Pharmacology Reference, Elsevier, 2007, pp. 1–2. doi: 10.1016/B978-008055232-3.61047-5.
Mohd. J. Naim et al., “Therapeutic journey of 2,4-thiazolidinediones as a versatile scaffold: An insight into structure activity relationship,” Eur J Med Chem, vol. 129, pp. 218–250, Mar. 2017, doi: 10.1016/j.ejmech.2017.02.031.
M. N. L. A. 1, P. S. 1, S. P. 1, M. N. B. 1 P. Mounika 1, “A Review on Thiazolidinedione,” Asian Journal of Pharmaceutical Research, vol. 7, no. 2, pp. 124–135, 2017.
N. Long, A. Le Gresley, and S. P. Wren, “Thiazolidinediones: An In–Depth Study of Their Synthesis and Application to Medicinal Chemistry in the Treatment of Diabetes Mellitus,” ChemMedChem, vol. 16, no. 11, pp. 1717–1736, Jun. 2021, doi: 10.1002/cmdc.202100177.
S. Wójtowicz, A. K. Strosznajder, M. Jeżyna, and J. B. Strosznajder, “The Novel Role of PPAR Alpha in the Brain: Promising Target in Therapy of Alzheimer’s Disease and Other Neurodegenerative Disorders,” Neurochem Res, vol. 45, no. 5, pp. 972–988, May 2020, doi: 10.1007/s11064-020-02993-5.
N. S. Tan, M. Vázquez-Carrera, A. Montagner, M. K. Sng, H. Guillou, and W. Wahli, “Transcriptional control of physiological and pathological processes by the nuclear receptor PPARβ/δ,” Prog Lipid Res, vol. 64, pp. 98–122, Oct. 2016, doi: 10.1016/j.plipres.2016.09.001.
M. Botta, M. Audano, A. Sahebkar, C. Sirtori, N. Mitro, and M. Ruscica, “PPAR Agonists and Metabolic Syndrome: An Established Role?,” Int J Mol Sci, vol. 19, no. 4, p. 1197, Apr. 2018, doi: 10.3390/ijms19041197.
S. Wójtowicz, A. K. Strosznajder, M. Jeżyna, and J. B. Strosznajder, “The Novel Role of PPAR Alpha in the Brain: Promising Target in Therapy of Alzheimer’s Disease and Other Neurodegenerative Disorders,” Neurochem Res, vol. 45, no. 5, pp. 972–988, May 2020, doi: 10.1007/s11064-020-02993-5.
Christofides, E. Konstantinidou, C. Jani, and V. A. Boussiotis, “The role of peroxisome proliferator-activated receptors (PPAR) in immune responses,” Metabolism, vol. 114, p. 154338, Jan. 2021, doi: 10.1016/j.metabol.2020.154338.
S. Tyagi, S. Sharma, P. Gupta, A. Saini, and C. Kaushal, “The peroxisome proliferator-activated receptor: A family of nuclear receptors role in various diseases,” J Adv Pharm Technol Res, vol. 2, no. 4, p. 236, 2011, doi: 10.4103/2231-4040.90879.
C. Janani and B. D. Ranjitha Kumari, “PPAR gamma gene – A review,” Diabetes & Metabolic Syndrome: Clinical Research & Reviews, vol. 9, no. 1, pp. 46–50, Jan. 2015, doi: 10.1016/j.dsx.2014.09.015.
D. B. Savage, K. F. Petersen, and G. I. Shulman, “Disordered Lipid Metabolism and the Pathogenesis of Insulin Resistance,” Physiol Rev, vol. 87, no. 2, pp. 507–520, Apr. 2007, doi: 10.1152/physrev.00024.2006.
B. Becker and R. A. Roth, “Insulin Receptor Structure and Function in Normal and Pathological Conditions,” Annu Rev Med, vol. 41, no. 1, pp. 99–115, Feb. 1990, doi: 10.1146/annurev.me.41.020190.000531.
E. Quinn, P. K. Hamilton, C. J. Lockhart, and G. E. McVeigh, “Thiazolidinediones: effects on insulin resistance and the cardiovascular system,” Br J Pharmacol, vol. 153, no. 4, pp. 636–645, Feb. 2008, doi: 10.1038/sj.bjp.0707452.
K. Lam, C. L. Carpenter, N. B. Ruderman, J. C. Friel, and K. L. Kelly, “The phosphatidylinositol 3-kinase serine kinase phosphorylates IRS-1. Stimulation by insulin and inhibition by Wortmannin.,” J Biol Chem, vol. 269, no. 32, pp. 20648–52, Aug. 1994.
M. Prentki and C. J. Nolan, “Islet beta cell failure in type 2 diabetes.,” J Clin Invest, vol. 116, no. 7, pp. 1802–12, Jul. 2006, doi: 10.1172/JCI29103.
Pernicova and M. Korbonits, “Metformin—mode of action and clinical implications for diabetes and cancer,” Nat Rev Endocrinol, vol. 10, no. 3, pp. 143–156, Mar. 2014, doi: 10.1038/nrendo.2013.256.
D. B. Savage, K. F. Petersen, and G. I. Shulman, “Disordered Lipid Metabolism and the Pathogenesis of Insulin Resistance,” Physiol Rev, vol. 87, no. 2, pp. 507–520, Apr. 2007, doi: 10.1152/physrev.00024.2006.
P. Tontonoz and B. M. Spiegelman, “Fat and beyond: the diverse biology of PPARgamma.,” Annu Rev Biochem, vol. 77, pp. 289–312, 2008, doi: 10.1146/annurev.biochem.77.061307.091829.
H. U. Hring, “The insulin receptor: signalling mechanism and contribution to the pathogenesis of insulin resistance,” Diabetologia, vol. 34, no. 12, pp. 848–861, Dec. 1991, doi: 10.1007/BF00400192.
R. T. Watson, “Intracellular Organization of Insulin Signaling and GLUT4 Translocation,” Recent Prog Horm Res, vol. 56, no. 1, pp. 175–194, Jan. 2001, doi: 10.1210/rp.56.1.175.
H. Yki-Järvinen, “Thiazolidinediones,” New England Journal of Medicine, vol. 351, no. 11, pp. 1106–1118, Sep. 2004, doi: 10.1056/NEJMra041001.
H. Hauner, “The mode of action of thiazolidinediones,” Diabetes Metab Res Rev, vol. 18, no. S2, pp. S10–S15, Mar. 2002, doi: 10.1002/dmrr.249.
M. J. Reginato and M. A. Lazar, “Mechanisms by which Thiazolidinediones Enhance Insulin Action,” Trends in Endocrinology & Metabolism, vol. 10, no. 1, pp. 9–13, Jan. 1999, doi: 10.1016/S1043-2760(98)00110-6.
H. Yki-Järvinen, “Thiazolidinediones and the liver in humans,” CurrOpinLipidol, vol. 20, no. 6, pp. 477–483, Dec. 2009, doi: 10.1097/MOL.0b013e3283321d37.
M. J. Reginato and M. A. Lazar, “Mechanisms by which Thiazolidinediones Enhance Insulin Action,” Trends in Endocrinology & Metabolism, vol. 10, no. 1, pp. 9–13, Jan. 1999, doi: 10.1016/S1043-2760(98)00110-6.
Berger et al., “Thiazolidinediones produce a conformational change in peroxisomal proliferator-activated receptor-gamma: binding and activation correlate with antidiabetic actions in db/db mice.,” Endocrinology, vol. 137, no. 10, pp. 4189–4195, Oct. 1996, doi: 10.1210/endo.137.10.8828476.
P. Tontonoz, E. Hu, R. A. Graves, A. I. Budavari, and B. M. Spiegelman, “mPPAR gamma 2: tissue-specific regulator of an adipocyte enhancer.,” Genes Dev, vol. 8, no. 10, pp. 1224–1234, May 1994, doi: 10.1101/gad.8.10.1224.
M. Gurnell, D. B. Savage, V. K. K. Chatterjee, and S. O’Rahilly, “The Metabolic Syndrome: Peroxisome Proliferator-Activated Receptor γ and Its Therapeutic Modulation,” J Clin Endocrinol Metab, vol. 88, no. 6, pp. 2412–2421, Jun. 2003, doi: 10.1210/jc.2003-030435.
R. F. Kletzien, L. A. Foellmi, P. K. Harris, B. M. Wyse, and S. D. Clarke, “Adipocyte fatty acid-binding protein: regulation of gene expression in vivo and in vitro by an insulin-sensitizing agent.,” Mol Pharmacol, vol. 42, no. 4, pp. 558–62, Oct. 1992.
Ibrahimiet al., “Evidence for a common mechanism of action for fatty acids and thiazolidinedione antidiabetic agents on gene expression in preadipose cells.,” Mol Pharmacol, vol. 46, no. 6, pp. 1070–6, Dec. 1994.
Mughal, D. Kumar, and A. Vikram, “Effects of Thiazolidinediones on metabolism and cancer: Relative influence of PPARγ and IGF-1 signaling,” Eur J Pharmacol, vol. 768, pp. 217–225, Dec. 2015, doi: 10.1016/j.ejphar.2015.10.057.
R. Da Ros, R. Assaloni, and A. Ceriello, “The preventive anti-oxidant action of thiazolidinediones: a new therapeutic prospect in diabetes and insulin resistance,” Diabetic Medicine, vol. 21, no. 11, pp. 1249–1252, Nov. 2004, doi: 10.1111/j.1464-5491.2004.01312.x.
V. T. Samuel, K. F. Petersen, and G. I. Shulman, “Lipid-induced insulin resistance: unravelling the mechanism.,” Lancet, vol. 375, no. 9733, pp. 2267–77, Jun. 2010, doi: 10.1016/S0140-6736(10)60408-4.
G. Yu et al., “The effect of thiazolidinediones on plasma adiponectin levels in normal, obese, and type 2 diabetic subjects.,” Diabetes, vol. 51, no. 10, pp. 2968–74, Oct. 2002, doi: 10.2337/diabetes.51.10.2968.
T. Yamauchi et al., “Cloning of adiponectin receptors that mediate antidiabetic metabolic effects.,” Nature, vol. 423, no. 6941, pp. 762–9, Jun. 2003, doi: 10.1038/nature01705.
S. P. Weisberg, D. McCann, M. Desai, M. Rosenbaum, R. L. Leibel, and A. W. Ferrante, “Obesity is associated with macrophage accumulation in adipose tissue,” Journal of Clinical Investigation, vol. 112, no. 12, pp. 1796–1808, Dec. 2003, doi: 10.1172/JCI19246.
Cariou, B. Charbonnel, and B. Staels, “Thiazolidinediones and PPARγ agonists: time for a reassessment,” Trends in Endocrinology & Metabolism, vol. 23, no. 5, pp. 205–215, May 2012, doi: 10.1016/j.tem.2012.03.001.
R. W. Nestoet al., “Thiazolidinedione Use, Fluid Retention, and Congestive Heart Failure,” Circulation, vol. 108, no. 23, pp. 2941–2948, Dec. 2003, doi: 10.1161/01.CIR.0000103683.99399.7E.
Shimoyama, K. Ogino, Y. Tanaka, T. Ikeda, and I. Hisatome, “Hemodynamic basis for the acute cardiac effects of troglitazone in isolated perfused rat hearts.,” Diabetes, vol. 48, no. 3, pp. 609–615, Mar. 1999, doi: 10.2337/diabetes.48.3.609.
N. Ghazziet al., “Cardiac and Glycemic Benefits of Troglitazone Treatment in NIDDM,” Diabetes, vol. 46, no. 3, pp. 433–439, Mar. 1997, doi: 10.2337/diab.46.3.433.
St. John Sutton et al., “A Comparison of the Effects of Rosiglitazone and Glyburide on Cardiovascular Function and Glycemic Control in Patients With Type 2 Diabetes,” Diabetes Care, vol. 25, no. 11, pp. 2058–2064, Nov. 2002, doi: 10.2337/diacare.25.11.2058.
T. Yue et al., “In Vivo Myocardial Protection From Ischemia/Reperfusion Injury by the Peroxisome Proliferator–Activated Receptor-γ Agonist Rosiglitazone,” Circulation, vol. 104, no. 21, pp. 2588–2594, Nov. 2001, doi: 10.1161/hc4601.099403.
Shiomiet al., “Pioglitazone, a Peroxisome Proliferator–Activated Receptor-γ Agonist, Attenuates Left Ventricular Remodeling and Failure After Experimental Myocardial Infarction,” Circulation, vol. 106, no. 24, pp. 3126–3132, Dec. 2002, doi: 10.1161/01.CIR.0000039346.31538.2C.
F. A. Masoudiet al., “Metformin and Thiazolidinedione Use in Medicare Patients With Heart Failure,” JAMA, vol. 290, no. 1, p. 81, Jul. 2003, doi: 10.1001/jama.290.1.81.
Lecka-Czernik, “Bone Loss in Diabetes: Use of Antidiabetic Thiazolidinediones and Secondary Osteoporosis,” CurrOsteoporos Rep, vol. 8, no. 4, pp. 178–184, Dec. 2010, doi: 10.1007/s11914-010-0027-y.
V. Schwartz and D. E. Sellmeyer, “Thiazolidinedione Therapy Gets Complicated,” Diabetes Care, vol. 30, no. 6, pp. 1670–1671, Jun. 2007, doi: 10.2337/dc07-0554.
M. Yamamoto, T. Yamaguchi, M. Yamauchi, H. Kaji, and T. Sugimoto, “Diabetic Patients Have an Increased Risk of Vertebral Fractures Independent of BMD or Diabetic Complications,” Journal of Bone and Mineral Research, vol. 24, no. 4, pp. 702–709, Apr. 2009, doi: 10.1359/jbmr.081207.
Falchetti, L. Masi, and M. L. Brandia, “Thiazolidinediones and bone.,” Clin Cases Miner Bone Metab, vol. 4, no. 2, pp. 103–7, May 2007.
Grey, “Thiazolidinedione-induced skeletal fragility - mechanisms and implications,” Diabetes ObesMetab, vol. 11, no. 4, pp. 275–284, Apr. 2009, doi: 10.1111/j.1463-1326.2008.00931.x.
R. Dormuth, G. Carney, B. Carleton, K. Bassett, and J. M. Wright, “Thiazolidinediones and Fractures in Men and Women,” Arch Intern Med, vol. 169, no. 15, p. 1395, Aug. 2009, doi: 10.1001/archinternmed.2009.214.
M. Chiu, L. McBeth, P. Sindhwani, and T. D. Hinds, “Deciphering the Roles of Thiazolidinediones and PPAR γ in Bladder Cancer,” PPAR Res, vol. 2017, pp. 1–9, 2017, doi: 10.1155/2017/4810672.
J. D. Lewis et al., “Risk of Bladder Cancer Among Diabetic Patients Treated With Pioglitazone,” Diabetes Care, vol. 34, no. 4, pp. 916–922, Apr. 2011, doi: 10.2337/dc10-1068.
J. D. Lewis et al., “Pioglitazone Use and Risk of Bladder Cancer and Other Common Cancers in Persons With Diabetes,” JAMA, vol. 314, no. 3, p. 265, Jul. 2015, doi: 10.1001/jama.2015.7996.
R. A. Lubet, S. M. Fischer, V. E. Steele, M. M. Juliana, R. Desmond, and C. J. Grubbs, “Rosiglitazone, a PPAR gamma agonist: Potent promoter of hydroxybutyl(butyl)nitrosamine-induced urinary bladder cancers,” Int J Cancer, vol. 123, no. 10, pp. 2254–2259, Nov. 2008, doi: 10.1002/ijc.23765.
Liu et al., “Identification of a novel selective agonist of PPARγ with no promotion of adipogenesis and less inhibition of osteoblastogenesis,” Sci Rep, vol. 5, no. 1, p. 9530, Apr. 2015, doi: 10.1038/srep09530.
Y. Guan, Y. Zhang, L. Davis, and M. D. Breyer, “Expression of peroxisome proliferator-activated receptors in urinary tract of rabbits and humans,” American Journal of Physiology-Renal Physiology, vol. 273, no. 6, pp. F1013–F1022, Dec. 1997, doi: 10.1152/ajprenal.1997.273.6.F1013.
C.-H. Tseng, “A Review on Thiazolidinediones and Bladder Cancer in Human Studies,” Journal of Environmental Science and Health, Part C, vol. 32, no. 1, pp. 1–45, Jan. 2014, doi: 10.1080/10590501.2014.877645.
T. A. Buchanan et al., “Preservation of Pancreatic β-Cell Function and Prevention of Type 2 Diabetes by Pharmacological Treatment of Insulin Resistance in High-Risk Hispanic Women,” Diabetes, vol. 51, no. 9, pp. 2796–2803, Sep. 2002, doi: 10.2337/diabetes.51.9.2796.
J. Chilcott, P. Tappenden, M. L. Jones, and J. P. Wight, “A systematic review of the clinical effectiveness of pioglitazone in the treatment of type 2 diabetes mellitus,” Clin Ther, vol. 23, no. 11, pp. 1792–1823, Nov. 2001, doi: 10.1016/S0149-2918(00)80078-8.
Einhorn, V. R. Aroda, and R. R. Henry, “Glitazones and the management of insulin resistance: what they do and how might they be used,” Endocrinol Metab Clin North Am, vol. 33, no. 3, pp. 595–616, Sep. 2004, doi: 10.1016/j.ecl.2004.04.003.
J. Lewin et al., “Effects of simvastatin on the lipid profile and attainment of low-density lipoprotein cholesterol goals when added to thiazolidinedione therapy in patients with type 2 diabetes mellitus: A multicenter, randomized, double-blind, placebo-controlled trial,” Clin Ther, vol. 26, no. 3, pp. 379–389, Jan. 2004, doi: 10.1016/S0149-2918(04)90033-1.
Antonelli et al., “Thiazolidinediones and antiblastics in primary human anaplastic thyroid cancer cells,” Clin Endocrinol (Oxf), vol. 70, no. 6, pp. 946–953, Jun. 2009, doi: 10.1111/j.1365-2265.2008.03415.x.
Y. Jiang et al., “Combination of thiazolidinedione and hydralazine suppresses proliferation and induces apoptosis by PPARγ up-expression in MDA-MB-231 cells,” Exp Mol Pathol, vol. 91, no. 3, pp. 768–774, Dec. 2011, doi: 10.1016/j.yexmp.2011.09.007.
S. Braunstein, “New developments in type 2 diabetes mellitus: Combination therapy with a thiazolidinedione,” Clin Ther, vol. 25, no. 7, pp. 1895–1917, Jul. 2003, doi: 10.1016/S0149-2918(03)80195-9.
H. R. Wolffenbuttel, R. Gomis, S. Squatrito, N. P. Jones, and R. N. Patwardhan, “Addition of low-dose rosiglitazone to sulphonylurea therapy improves glycaemic control in Type 2 diabetic patients,” Diabetic Medicine, vol. 17, no. 1, pp. 40–47, Jan. 2000, doi: 10.1046/j.1464-5491.2000.00224.x.
J. A. Kiayias, E. D. Vlachou, E. Theodosopoulou, and E. Lakka-Papadodima, “Rosiglitazone in Combination With Glimepiride Plus Metformin in Type 2 Diabetic Patients,” Diabetes Care, vol. 25, no. 7, pp. 1251–1252, Jul. 2002, doi: 10.2337/diacare.25.7.1251.
R. A. Costello, S. Nicolas, and A. Shivkumar, Sulfonylureas. 2023.
“Thiazolidinediones,” in Meyler’s Side Effects of Drugs, Elsevier, 2016, pp. 851–873. doi: 10.1016/B978-0-444-53717-1.01536-5.
Z. Milner and H. Akhondi, Repaglinide. 2023.
L. Di Magno, F. Di Pastena, R. Bordone, S. Coni, and G. Canettieri, “The Mechanism of Action of Biguanides: New Answers to a Complex Question,” Cancers (Basel), vol. 14, no. 13, p. 3220, Jun. 2022, doi: 10.3390/cancers14133220.
L. A. McIver, C. V. Preuss, and J. Tripp, Acarbose. 2023.
H. Hauner, “The mode of action of thiazolidinediones,” Diabetes Metab Res Rev, vol. 18, no. S2, pp. S10–S15, Mar. 2002, doi: 10.1002/dmrr.249.
and L. B. C. P. C. James R. LaSalle, “Oral Combination Therapy With Thiazolidinediones in Type 2 Diabetes,” Am J Manag Care, vol. 12, pp. 369–381, 2006.